COLLEGEVILLE, PA — Thubrikar Aortic Valve, Inc. has announced promising outcomes from recent procedures involving its Optimum Transcatheter Aortic Valve (Optimum TAV™) and Precision 2™ Delivery Catheter. Five additional patients have been successfully implanted, showcasing the effectiveness of the valve system even in challenging anatomical cases.
The procedures were performed by Dr. Jaroslaw Trebacz, an Interventional Cardiologist and Principal Investigator of the TAVI-1 CE Mark trial, at the John Paul II Hospital in Krakow, Poland. Dr. Trebacz noted the superior procedural results achieved with the Optimum TAV and its second-generation delivery system, stating, “I wish all my routine TAVR patients had the same procedural results we have achieved with the Optimum TAV and 2nd-generation delivery system.”
Dr. Trebacz is set to present these findings at the Transcatheter Cardiovascular Therapeutics (TCT) Conference on October 28, during the “Innovations in TAVR Systems and New Clinical Updates” session.
The Optimum TAVI System, which includes the Optimum TAV and the Precision 2 Catheter, is designed to address the durability needs of a younger patient demographic. It stands out as the only short and self-expanding valve platform available. Dr. Mano Thubrikar, Founder and President of Thubrikar Aortic Valve, underscored the valve’s durability, stating, “Two-year follow-up data from the TAVI-1 trial confirm the pressure gradient and effective orifice area of the Optimum TAV continue to be superior to that published on any other TAV of similar size. The Optimum TAV is engineered to excel in durability, as evidenced by its outstanding preclinical durability and clinical results.”
To date, the Optimum TAV has been implanted in 13 patients, with the first global patient maintaining excellent health nearly six years post-procedure. Thubrikar Aortic Valve plans to continue its CE Mark trial by expanding to two additional European countries, with authorization to implant at least eight more patients in Poland. This expansion highlights the company’s commitment to advancing treatment options for patients requiring aortic valve replacements.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.